Table 3.

Age-adjusted Cox models relating COMT rs4680 val allele (met allele as reference) and rs4818 G allele associations (C allele as reference) to incident major CVD and total CVD, stratified by randomized treatment assignment.

SNP*	Outcome†	Treatment Arm	HR[95% CI], p‡	Gene-drug int. p§
rs4680	Major CVD	Placebo‖	0.66 [0.51-0.84], p=0.0007	--
		Aspirin only	1.13 [0.88-1.45], p=0.34	0.002
		Vitamin E only	1.08 [0.84-1.38], p= 0.52	0.004
	Total CVD	Placebo	0.77 [0.63-0.93], p=0.0075	--
		Aspirin only	1.10 [0.90-1.40], p=0.23	0.011
		Vitamin E only	1.09 [0.90-1.32], p=0.38	0.011
rs4818	Major CVD	Placebo	0.67 [0.51-0·86], p=0.0022	--
		Aspirin only	1.22 [0.95-1.56], p=0.11	0.0009
		Vitamin E only	1.03 [0.80-1.32], p=0.80	0.016
	Total CVD	Placebo	0.70 [0.57-0.87], p=0.001	--
		Aspirin only	1.14 [0.93-1.40], p=0.20	0.001
		Vitamin E only	1.06 [0.87-1.29], p=0.57	0.005

^*rs4680 coded allele = G(val), reference allele = A(met); rs4818 coded allele = G, reference allele = C.

^†Major CVD, the primary WHS outcome is a composite of myocardial infarction, stroke or death from cardiovascular causes. Total CVD, is a composite of revascularization procedures (percutaneous transluminal coronary angioplasty, coronary bypass graft), in addition to events in the primary outcome.

^‡Hazard ratios refer to SNP associations with incident CVD in designated treatment arms.

^§Gene-drug interaction p-value refers to the significance of the difference between the SNP association among placebo allocated WGHS participants and participants allocated to the designated treatment arm.

^‖Placebo results are also reported in Table 1.